Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OCGN
STRONG SELLOcugen, Inc. · Healthcare · United States · $410M · Avg Vol: $11M/d
COMPANY DESCRIPTION
Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccines for infectious diseases. Its strategic partnerships, particularly for vaccine development, alongside a proprietary modifier gene therapy platform for ocular diseases, offer diversification in a high-risk, high-reward sector. Ocugen is a clinical-stage biotechnology company pursuing both gene therapy solutions for rare eye diseases and broader public health initiatives.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.5M | 6.0M | 4.1M | 4.4M | 21.0% | 4.5M | 4.4M | 11.0M | 58.0% |
| EPS | -0.38 | -0.26 | -0.20 | -0.23 | — | -0.23 | -0.22 | -0.23 | — |
| Shares | 221.6M | 256.6M | 291.4M | 312.4M | +41.0% | 338.5M | — | — | — |
| Debt | 6.4M | 6.9M | 32.5M | 33.1M | 73.2% | 33.3M | — | — | — |
| Equity | 74.0M | 40.6M | 29.6M | -12.2M | -36.7% | — | — | — | — |
| Op CF | -60.1M | -62.1M | -42.1M | -57.0M | — | -59.4M | — | — | — |
| Inv CF | -17.0M | 3.1M | -3.4M | -0.3M | — | — | — | — | — |
| Fin CF | 59.5M | 20.9M | 64.9M | 17.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OCGN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OCGN | Ocugen, Inc.(you) | $410M | 1 | STRONG SELL |
| LYEL | Lyell Immunopharma, Inc. | $309M | 2 | STRONG SELL |
| EVMN | Evommune, Inc. | $409M | 7 | STRONG SELL |
| PRME | Prime Medicine, Inc. | $533M | 3 | STRONG SELL |
| CMPX | Compass Therapeutics, Inc. | $373M | 7 | STRONG SELL |
| EDIT | Editas Medicine, Inc. | $399M | 8 | STRONG SELL |
| PROK | ProKidney Corp. | $453M | 7 | STRONG SELL |
| UPB | Upstream Bio, Inc. | $349M | 8 | STRONG SELL |
| INDP | Indaptus Therapeutics, Inc. | $348M | 8 | STRONG SELL |
| SPRY | ARS Pharmaceuticals, Inc. | $590M | 5 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%